Stock PFE PFIZER, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Pfizer, Inc.

Equities

PFE

US7170811035

Market Closed - Nyse
Other stock markets
 04:00:51 2024-06-04 pm EDT 		5-day change 1st Jan Change
29.49 USD +0.61% Intraday chart for Pfizer, Inc. +4.20% +2.43%
Jun. 04 Pfizer: article on Lyme vaccine in The Lancet CF
Jun. 04 Pfizer Partners with Abu Dhabi to Advance Research on Sickle Cell Disease MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pfizer: article on Lyme vaccine in The Lancet
CF
Pfizer Partners with Abu Dhabi to Advance Research on Sickle Cell Disease
MT
Delhi HC's Ruling In Pfizer vs. Renovision; An Analysis
AQ
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
BU
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints
MT
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says
RE
Pfizer: positive trial in large B-cell lymphoma
CF
Pfizer: promising trial in Hodgkin lymphoma
CF
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed
RE
GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac Cases
MT
Delaware judge lets more than 70,000 Zantac lawsuits go forward
RE
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
BU
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
BU
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
CI
Sector Update: Health Care Stocks Higher Late Afternoon
MT
Sector Update: Health Care Stocks Advance Friday Afternoon
MT
Sector Update: Health Care
MT
Pfizer Reports Encouraging Long-Term Trial Results of Advanced Lung Cancer Drug
MT
US FDA approves Moderna's RSV vaccine, its second marketed product
RE
Patents, Policies And Privacy: The Highs And Lows Of Technology In IP
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.